Hygtia Therapeutics
Company
Hygtia Therapeutics develops one asset, in phase 1 (ISM8969 in obese adult participants at risk of cardiovascular disease). Mostly small molecule acting on NLRP3 and NLRP3 inflammasome.
- 1
- Asset
- Furthest stage
- Phase 1
- 0
- Trials
- 1
- Signal
Pipeline
1Oral brain-penetrant NLRP3 inflammasome inhibitor for chronic neuroinflammation
Phase 1, Small molecule, NLRP3, NLRP3 inflammasome, obese adult participants at risk of cardiovascular disease, Parkinson's disease (Preclinical), Partner
Full company profiles: pipeline, trials, funding and people.
In the full profile
- Evidence behind the mechanisms2
- Signals2
- Similar companies6